Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Provided By GlobeNewswire
Last update: Feb 7, 2025
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 45,000 shares of its common stock under the Company’s 2023 Inducement Plan.
Read more at globenewswire.com6.9
+0.05 (+0.73%)
Find more stocks in the Stock Screener
TPST Latest News and Analysis
11 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.Let's have a look at the gap up and gap down stocks in today's session.
11 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
